“Long-Term Management of Moderate-to-Severe Plaque Psoriasis: Maintenance of Treatment Success Following Cessation of Halobetasol Propionate 0.01%/Tazarotene 0.045% Lotion”, J of Skin, vol. 4, no. 6, p. s79, Oct. 2020, doi: 10.25251/skin.4.supp.79.